Undifferentiated Embryonal Sarcoma of the Liver: Evaluation of the Relapse Profile According to the Therapies Administered

Undifferentiated Embryonal Sarcoma of the Liver

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05640960

Acronym

SARCOM

Enrollment

Registered

2022-12-07

Start date

2020-09-11

Completion date

2021-12-31

Last updated

2023-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Sarcoma

Keywords

Embryonal Sarcoma, Embryonic Sarcoma, Hepatoblastoma, Hepatocarcinoma, Hepatic Sarcoma, Undifferentiated (Embryonal) Sarcoma

Brief summary

Undifferentiated embryonal sarcoma of the liver is the 3rd most common malignant liver tumor after hepatoblastoma and hepatocellular carcinoma with a peak incidence between 6 and 10 years of age. Historically, it is a tumor treated only by surgery with a poor prognosis. In the last decade, the combination of more intensive chemotherapy and, more randomly, radiotherapy, has significantly improved the survival rate of these patients. Due to its low incidence, there are few series reported in the literature and to date there is no specific treatment protocol for the management of these tumors. It seems appropriate to review the management of these tumors in France in order to discuss the best therapeutic strategy.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 25 Years

Inclusion criteria

* Any patient aged 0 to 25 on the date of inclusion in the study * Treatment carried out in France (included in NRSTS 2005, in the childhood cancer registry or in an SFCE center) * Start of treatment from 01/01/2008 to 31/12/2018 * Diagnosis of undifferentiated embryonal sarcoma of the liver defined by a compatible histological analysis * Adult subject who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research * Minor subject (and/or his parental authority) who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research

Exclusion criteria

* Refusal to participate in this research * Diagnosis of rhabdoid tumor, rhabdomysarcomas, angiosarcomas, PNET * Absence of histological and/or molecular documentation.

Design outcomes

Primary

Measure	Time frame	Description
Describe the relapse profile of children with undifferentiated hepatic sarcoma according to the therapies received	3 years after treatment	the primary endpoint is event-free survival (progression, death, relapse) at 3 years.

Countries

France

Outcome results